CNS Pharmaceuticals, Inc. - 10-Q Filing
CNS Pharmaceuticals reports Q3 2026 net loss of $2.5 million and cash position increase to $17.2 million.
Tickers: $CNSP
Read the full article at SEC EDGAR
Part of the story InMed Pharmaceuticals Inc. - 8-K Filing (3 articles)